FOLH1 and posterior cortical atrophy: Among them, urea-based inhibitors (Figure 1A) containing a Glu-Urea core motif that binds to PSMA protein with high efficiency and specificity currently dominate in clinical trials for specific imaging and radioligand therapy of PCa (4–13), such as 68Ga-PSMA-11 (the first PSMA agent for PET imaging approved by the U.S. Food and Drug Administration), 68Ga/177Lu/225Ac-PSMA-617, 18F-PSMA-1007, 18F-DCFPyL, Al18F-PSMA-BCH, 99mTc-MIP-1404, 99mTc-PSMA-I&S and 18F-rhPSMA-7.3 (14–18).